2 Corporate Drive
South San Francisco
About PACT Pharma
PACT Pharma is an exciting, well-funded clinical stage company developing personalized adoptive T cell therapies for the eradication of solid tumors. Our private designer T cells are created by analyzing a patient’s individual tumor and engineering T cells to kill that specific tumor. In principle, this technology can be used to treat any cancer type.
PACT is developing tumor-mutation targeted T Cells tailored for each patient. Tumor mutation neoepitope (neoE) targeting is programmed into the patient's own T cells to seek out & kill the tumors. Using (non-viral) precision genome engineering, the neoE-targeted T cell receptors (TCRs) replace the endogenous TCR of fresh CD8 and CD4 T cells collected from that same patient followed by minimal expansion in closed systems for re-infusion into the patient. These patient-specific neoTCR-P1 cells are formulated to immediately kill all neoantigen-expressing tumors, together with a deep reservoir of `ready-to-go' neoTCR-P1 cells for long term persistence and capable of rapid expansion to prevent future cancer recurrence.
If you desire a stimulating fast paced environment working with intelligent people who are making an impact in cancer, you will want to join the PACT Pharma team. We are a rapidly expanding, innovative, and collaborative team working towards one main goal: eradicating cancer!
We are in the San Francisco bay area, the heart of the world’s premier biotechnology research hub. PACT Pharma offers a competitive compensation and benefits package, including participation in the aggressive growth of the company in the form of stock option grants.
6 articles with PACT Pharma
--Companies will leverage their highly complementary technologies to address target specificity for tumor cells and cell exhaustion, two significant barriers for solid tumor T cell therapy--
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
Mehra brings significant experience scaling organizations, an important skill as PACT grows and enters the clinic.
Moore led development of one of only two FDA-approved CAR-T therapies.
Personalized gene-edited immune cell therapy for patients with solid cancers: New data establishes approach for verifying patient-specific cancer mutation targets
PACT's gene-edited T cells were observed to kill tumor cells by targeting patient-specific tumor mutation targets in non-clinical testing
Taiho Ventures, the corporate venture capital arm of Taiho Pharmaceutical, has pumped up its venture capital pool from $50 million to $300 million. It also indicates it plans to accelerate its “open innovation” through the investments.